Today, BioPharma Dive is switching up its usual rundown of industry news to highlight some notable clinical trial updates presented at the annual meeting of the American Diabetes Association. Over the weekend, several large pharmaceutical companies released new study data on prospects they hope will eventually become part of the next wave of weight loss medicines.
By and large, companies are hoping to break into a market currently dominated by Eli Lilly and Novo Nordisk. But Lilly and Novo are advancing their own new medicines, too, in a bid to stay ahead of the competition.
Below are three notable datasets and a look at how they’re being interpreted by investors and analysts.
Lilly’s reinforced ‘dominance’
Lilly is already the market leader in obesity. Its top drug, sold as Zepbound for obesity and Mounjaro for diabetes, has become the world’s best-selling medicine. And a newly launched oral medication, Foundayo, is seen by analysts as a future blockbuster.
